DONATEBlood Cancer Treatment
Overview
Blood cancers are complex disorders that affect the production and function of blood cells, often requiring specialised and carefully coordinated treatment. Unlike solid tumours, these malignancies involve the bone marrow, lymphatic system, and circulating blood, making precise diagnosis and tailored therapy essential for effective control. Conditions such as leukaemia, lymphoma, and multiple myeloma demand expertise not only in chemotherapy but also in advanced molecular diagnostics, immunotherapy, and stem cell transplantation.
At RGCIRC (Rajiv Gandhi Cancer Institute & Research Centre), blood cancer treatment is delivered through a dedicated haemato-oncology and transplant programme that integrates advanced diagnostics, targeted therapies, CAR-T cell therapy, and comprehensive supportive care. With structured multidisciplinary planning and specialised infrastructure, treatment is designed to address both disease eradication and long-term recovery.
Understanding Blood Cancer and its Types
Blood cancer refers to a group of malignancies that originate in the bone marrow or lymphatic system and interfere with the normal production and function of blood cells. Because these cancers arise in the cells responsible for immunity, oxygen transport, and clotting, their impact is often systemic rather than confined to a single organ.
The main types of blood cancer include:
Leukaemia
Lymphoma develops in the lymphatic system, which forms part of the body’s immune defence. It typically presents with enlargement of lymph nodes and may involve other organs depending on the subtype.
Multiple Myeloma
Multiple myeloma arises from plasma cells within the bone marrow. It can disrupt normal antibody production, weaken bones, and affect kidney function.
Although these cancers differ in origin and behaviour, they share a common feature - disruption of healthy blood cell formation. Accurate classification through specialised diagnostic testing is essential, as treatment strategies vary significantly depending on the specific subtype and molecular profile.
When is Blood Cancer Treatment Required?
Blood cancer treatment is initiated based on the specific subtype, stage of disease, molecular profile, and the patient’s overall clinical condition. While some blood cancers require immediate therapy, others may be monitored closely until treatment becomes necessary. Treatment is typically advised in the following situations:
At Initial Diagnosis
In aggressive forms of leukaemia, high-grade lymphoma, or symptomatic multiple myeloma, treatment begins soon after diagnosis to control rapidly multiplying cancer cells and prevent complications.
High-Risk or Advanced Disease
When diagnostic testing reveals high-risk genetic or molecular features, early and intensive treatment may be recommended to improve long-term outcomes.
Symptomatic Disease Progression
If the disease leads to significant anaemia, infections, bleeding tendencies, organ involvement, or bone damage, prompt treatment is required to stabilise the condition.
Relapse or Refractory Disease
If cancer returns after initial therapy or does not respond adequately, second-line treatments, targeted therapy, immunotherapy, or advanced options such as stem cell transplantation or CAR-T cell therapy may be considered.
Because treatment strategies vary widely across different blood cancers, decisions are guided by detailed diagnostic evaluation and multidisciplinary consultation to ensure that therapy is both timely and appropriately tailored.
Advanced Diagnostics for Blood Cancer at RGCIRC
Effective treatment begins with precise diagnosis. Because blood cancers vary widely in behaviour and response to therapy, detailed laboratory and molecular evaluation is essential to classify the disease accurately and guide personalised treatment planning. At RGCIRC, advanced diagnostic capabilities support evidence-based decision-making from the outset.
The diagnostic work-up may include:
Bone Marrow Biopsy and Aspiration
A bone marrow examination allows direct assessment of abnormal blood cell production. It helps determine the type of blood cancer, disease burden, and response to treatment over time.
Flow Cytometry
Flow cytometry analyses specific markers on blood or bone marrow cells, enabling accurate classification of leukaemia and lymphoma subtypes. This technique plays a crucial role in identifying immunophenotypic characteristics of cancer cells.
Symptomatic Disease Progression
If the disease leads to significant anaemia, infections, bleeding tendencies, organ involvement, or bone damage, prompt treatment is required to stabilise the condition.
Cytogenetics and Molecular Profiling
Chromosomal analysis and molecular testing detect genetic abnormalities that influence prognosis and treatment strategy. Certain mutations may guide the use of targeted therapies or indicate the need for more intensive treatment.
Next-Generation Sequencing (NGS)
NGS provides detailed genetic mapping of cancer cells, helping identify actionable mutations and refine risk stratification. This supports precision medicine approaches in haemato-oncology.
PET-CT Imaging
For lymphomas and selected cases, PET-CT scans help assess disease spread, monitor treatment response, and detect residual disease.
By integrating advanced laboratory diagnostics with imaging and pathology expertise, RGCIRC ensures that blood cancer treatment is based on accurate classification and comprehensive risk assessment.
Types of Blood Cancer Treatments Available at RGCIRC
Treatment for blood cancer is highly individualised and depends on the specific subtype, stage, molecular characteristics, and overall health of the patient. At RGCIRC, therapy is planned within a dedicated haemato-oncology programme that integrates conventional treatments with advanced targeted and cellular therapies.
The available treatment options include:
Chemotherapy
Chemotherapy uses anti-cancer medicines to destroy rapidly dividing cancer cells. It may be administered as a single agent or in combination regimens, depending on the type and aggressiveness of the disease.
Targeted Therapy
Targeted therapy focuses on specific molecular pathways or genetic mutations driving cancer growth. By acting on defined cellular targets, these medicines can improve treatment precision while limiting damage to healthy cells.
Immunotherapy
Immunotherapy enhances the body’s immune response against cancer cells. This approach is commonly used in certain lymphomas and other haematological malignancies, either alone or in combination with chemotherapy.
CAR-T Cell Therapy
Chimeric Antigen Receptor T-cell (CAR-T) therapy is an advanced form of cellular immunotherapy used in selected B-cell malignancies. In this treatment, a patient’s own T-cells are genetically modified in a specialised laboratory to recognise and attack cancer cells before being infused back into the body. CAR-T therapy represents a significant advancement in the management of relapsed or refractory blood cancers and is offered in carefully selected cases within specialised treatment protocols.
Stem Cell / Bone Marrow Transplantation
Stem cell transplantation may be recommended in high-risk, relapsed, or certain aggressive blood cancers. This procedure replaces diseased bone marrow with healthy stem cells to restore normal blood cell production.
Radiation Therapy
In selected lymphoma cases, radiation therapy may be used to target specific disease sites as part of a combined treatment strategy.
By combining conventional chemotherapy with targeted agents, immunotherapy, cellular therapy, and transplant expertise, RGCIRC delivers comprehensive blood cancer treatment tailored to each patient’s disease profile.
Bone Marrow Transplant Programme
For certain high-risk, relapsed, or aggressive blood cancers, stem cell transplantation, commonly referred to as bone marrow transplant, forms a critical part of treatment. This procedure aims to replace diseased or damaged bone marrow with healthy stem cells, thereby restoring normal blood cell production and strengthening long-term disease control.
At RGCIRC, the Bone Marrow Transplant (BMT) programme is delivered within a specialised transplant unit supported by experienced haemato-oncologists, transplant physicians, intensivists, and infection control teams.
The transplant options include:
Autologous Stem Cell Transplant
In this approach, the patient’s own healthy stem cells are collected prior to high-dose chemotherapy and later reinfused to restore bone marrow function. It is commonly used in conditions such as multiple myeloma and selected lymphomas.
Allogeneic Stem Cell Transplant
Allogeneic transplantation involves stem cells from a compatible donor. This approach may be recommended in certain leukaemias and high-risk blood cancers, where donor immune cells can help eliminate residual cancer cells.
Conditioning Regimens
Before transplantation, patients undergo conditioning therapy, which may include high-dose chemotherapy or radiation, to eliminate cancer cells and prepare the bone marrow to receive new stem cells.
Dedicated HEPA-Filtered Sterile Isolation Units
During the neutropenic phase following transplantation, patients are particularly vulnerable to infections. RGCIRC’s transplant programme includes dedicated HEPA-filtered sterile isolation rooms designed to minimise exposure to airborne pathogens and support safe recovery during this critical period.
With specialised infrastructure, strict infection control protocols, and comprehensive monitoring, the transplant programme at RGCIRC is structured to provide advanced care within a carefully controlled environment.
Multidisciplinary Haemato-Oncology and Paediatric Expertise
Blood cancer treatment often requires coordinated care across multiple specialties, as therapy may involve complex chemotherapy protocols, transplant procedures, infection management, and long-term monitoring. At RGCIRC, treatment is guided by a structured haemato-oncology team that brings together expertise across adult and paediatric care.
The multidisciplinary framework includes:
Adult Haemato-Oncology Specialists
Experienced haematologists and medical oncologists lead the diagnosis and management of leukaemia, lymphoma, and multiple myeloma. Treatment protocols are tailored based on disease subtype, molecular findings, and patient-specific factors.
Paediatric Haemato-Oncology Unit
Recognising that a significant proportion of blood cancers, particularly acute leukaemia, affect children, RGCIRC provides dedicated paediatric haemato-oncology services. Treatment for children is delivered using age-appropriate protocols within a specialised care environment that addresses both medical and developmental needs.
Transplant Physicians and Critical Care Support
For patients undergoing stem cell transplantation or intensive therapy, transplant specialists and critical care teams ensure continuous monitoring and rapid management of complications.
Infectious Disease and Supportive Care Specialists
Given the high risk of infection during chemotherapy and transplant, infectious disease experts and infection control teams play an essential role in treatment planning and monitoring.
By integrating adult and paediatric expertise within a coordinated haemato-oncology framework, RGCIRC ensures that blood cancer care is comprehensive, age-appropriate, and supported by specialised infrastructure.
Pre-Treatment Evaluation
Before initiating therapy, a comprehensive evaluation is conducted to ensure that treatment is both safe and appropriately tailored to the specific type of blood cancer. Because therapies such as chemotherapy, immunotherapy, and stem cell transplantation can be intensive, careful assessment helps optimise outcomes and reduce potential risks.
The evaluation process typically includes:
Comprehensive Blood and Bone Marrow Testing
Detailed blood investigations and, where indicated, repeat bone marrow assessment help confirm disease status and establish a baseline for monitoring treatment response.
Organ Function Assessment
Heart, liver, kidney, and lung function are evaluated prior to starting therapy. This ensures that treatment intensity can be adjusted safely according to individual tolerance.
Infection Screening
Patients are screened for underlying infections, including viral markers, as immunosuppressive therapy can increase vulnerability. Preventive measures are planned accordingly.
Molecular and Genetic Risk Stratification
Advanced molecular testing and cytogenetic analysis help categorise disease risk and guide selection of targeted therapy, transplant decisions, or advanced options such as CAR-T cell therapy.
Through structured pre-treatment evaluation, therapy is initiated within a carefully planned and individualised framework designed to balance efficacy with safety.
Supportive and Comprehensive Care
Blood cancer treatment often extends over several months and, in some cases, years. During this time, supportive care plays a critical role in maintaining strength, preventing complications, and improving quality of life. At RGCIRC, supportive services are integrated alongside active cancer therapy to ensure that patients receive comprehensive and continuous care.
Supportive care measures include:
Infection Prevention and Monitoring
Because chemotherapy and transplant procedures can weaken the immune system, strict infection control protocols are implemented. Preventive medications, regular monitoring, and protective isolation when required help reduce infection risk.
Blood Component Therapy
Transfusions of red blood cells or platelets may be required when blood counts fall during treatment. These supportive interventions help manage anaemia, bleeding tendencies, and fatigue.
Nutritional Guidance
Maintaining adequate nutrition is essential during therapy. Personalised dietary counselling supports recovery, energy levels, and immune function.
Psychological and Emotional Support
A diagnosis of blood cancer can be emotionally challenging. Counselling services and psychosocial support help patients and families cope with stress and uncertainty throughout the treatment journey.
Symptom and Pain Management
Treatment-related side effects such as nausea, fatigue, or discomfort are actively managed through evidence-based supportive protocols to maintain comfort and wellbeing.
By combining active treatment with structured supportive care, RGCIRC ensures that therapy is not only focused on disease control but also on sustaining overall health and resilience.
Treatment Risks and Safety Protocols at RGCIRC
Blood cancer treatment can be intensive, particularly when high-dose chemotherapy, stem cell transplantation, or advanced cellular therapies are involved. While these treatments are designed to achieve effective disease control, they may also temporarily affect immunity and organ function. At RGCIRC, comprehensive safety protocols are implemented to minimise risk and ensure continuous monitoring.
Key safety considerations include:
Infection Risk During Treatment
Chemotherapy and transplant procedures can lower white blood cell counts, increasing vulnerability to infection. Preventive medications, regular laboratory monitoring, and protective isolation measures are used to reduce this risk.
Monitoring in HEPA-Filtered Isolation Units
Patients undergoing stem cell transplantation are cared for in dedicated HEPA-filtered sterile isolation rooms during the neutropenic phase. These specialised units are designed to minimise exposure to airborne pathogens and provide a controlled recovery environment.
Treatment-Related Toxicities
Certain therapies may affect the heart, liver, kidneys, or other organs. Baseline organ function testing and ongoing surveillance help detect and manage potential side effects promptly.
Cytokine Release Syndrome in CAR-T Therapy
CAR-T cell therapy may, in selected cases, trigger an immune response known as cytokine release syndrome. Treatment protocols include specialised monitoring and rapid intervention strategies to manage this condition safely.
Through structured monitoring, specialised infrastructure, and multidisciplinary oversight, blood cancer treatment at RGCIRC is delivered within a carefully supervised and patient-focused framework.
Cost of Blood Cancer Treatment in Delhi
The cost of blood cancer treatment varies depending on the type of malignancy, stage of disease, and the treatment protocol required. Because therapy may involve chemotherapy, targeted agents, immunotherapy, stem cell transplantation, or CAR-T cell therapy, financial planning is tailored to the individual clinical pathway.
The following factors commonly influence overall cost:
Type of Blood Cancer
Leukaemia, lymphoma, and multiple myeloma differ significantly in treatment duration and intensity, which may affect overall expenditure.
Treatment Protocol and Duration
Standard chemotherapy regimens, targeted therapies, long-term maintenance therapy, or advanced cellular therapies such as CAR-T may vary in cost depending on complexity and duration.
Stem Cell Transplant Requirement
Autologous or allogeneic transplantation involves specialised infrastructure, including sterile isolation units and extended monitoring, which can influence overall treatment planning.
Hospital Stay and Supportive Care
Length of hospitalisation, need for transfusions, infection management, and intensive monitoring are additional considerations.
Institutional Oncology Care with Transparent Pricing
RGCIRC operates as a philanthropic society, delivering institutional-grade oncology care through structured and transparent pricing models designed to make advanced cancer treatment more accessible. By integrating diagnostics, therapy, transplant services, and supportive care within a dedicated cancer centre, treatment planning remains comprehensive and clearly defined.
For personalised cost information based on individual treatment requirements, patients are encouraged to contact the hospital directly.
Why Choose RGCIRC for Blood Cancer Treatment in Delhi?
Choosing the right centre for blood cancer treatment is critical, as outcomes depend on accurate diagnosis, access to advanced therapies, specialised infrastructure, and continuous supportive care. At RGCIRC, blood cancer management is delivered within a dedicated haemato-oncology and transplant programme designed to combine clinical precision with comprehensive patient support.
The distinguishing strengths of treatment at RGCIRC include:
Dedicated Haemato-Oncology and Transplant Team
Experienced haematologists, medical oncologists, transplant physicians, and critical care specialists work together to manage both adult and paediatric blood cancers. Treatment plans are individualised based on disease subtype, molecular profile, and overall health status.
Advanced Molecular and Cellular Therapies
RGCIRC offers access to targeted therapy, immunotherapy, stem cell transplantation, and CAR-T cell therapy for selected B-cell malignancies. Integration of advanced molecular diagnostics supports precision-driven treatment selection.
Comprehensive Transplant Infrastructure with HEPA Units
The Bone Marrow Transplant programme includes dedicated HEPA-filtered sterile isolation rooms, structured infection control protocols, and specialised nursing support during the neutropenic phase. This infrastructure is critical for ensuring safety during high-intensity treatment.
Integrated Adult and Paediatric Expertise
With specialised services for both adult and paediatric patients, RGCIRC provides age-appropriate treatment protocols within a coordinated haemato-oncology framework.
By combining advanced diagnostics, modern therapeutic options, specialised transplant facilities, and structured supportive care, RGCIRC delivers blood cancer treatment that is comprehensive, carefully supervised, and centred on long-term recovery.
Recovery and Long-Term Follow-Up
Blood cancer treatment often continues beyond the initial phase of active therapy, and structured follow-up is essential to maintain remission, monitor for relapse, and manage long-term effects of treatment. At RGCIRC, follow-up care is organised within a defined surveillance pathway to ensure continuity and timely intervention when required.
Long-term follow-up typically includes:
Scheduled Surveillance Testing
Regular blood tests, bone marrow evaluations when indicated, and imaging studies are performed to assess treatment response and detect any early signs of disease recurrence.
Post-Transplant Monitoring
Patients who undergo stem cell transplantation require close monitoring for graft function, infection risk, and transplant-related complications. Follow-up visits are structured to address these specialised needs.
Monitoring for Late Effects of Treatment
Certain therapies may have delayed effects on organ function or immunity. Periodic assessment helps identify and manage these concerns proactively.
Immunisation and Infection Prevention Guidance
After intensive therapy or transplant, vaccination schedules and infection prevention strategies are reviewed to support immune recovery.
Through coordinated surveillance and supportive follow-up, long-term care at RGCIRC is designed to reinforce sustained remission and overall wellbeing.
Recovery and Long-Term Follow-Up
A diagnosis of blood cancer often brings uncertainty, but it also marks the beginning of a carefully guided treatment journey. With advances in targeted therapy, stem cell transplantation, and cellular immunotherapy, many blood cancers today are managed with increasing precision and improved outcomes. Recovery may take time, particularly when treatment is intensive, yet structured follow-up and supportive care help patients rebuild strength step by step.
At RGCIRC, blood cancer treatment is delivered within a dedicated haemato-oncology framework that integrates advanced diagnostics, specialised transplant infrastructure, and comprehensive supportive services. The focus remains not only on controlling the disease but also on supporting long-term resilience and quality of life.
To consult a specialist or learn more about blood cancer treatment, simply call +91-11-47022222.
Frequently Asked Questions
Q: What are the first signs of blood cancer?
Early signs may vary depending on the type of blood cancer but can include persistent fatigue, frequent infections, unexplained bruising or bleeding, enlarged lymph nodes, or bone pain. Because symptoms are often non-specific, medical evaluation and blood testing are important for accurate diagnosis.
Q: How is blood cancer diagnosed?
Diagnosis typically involves blood tests, bone marrow examination, flow cytometry, and molecular or genetic testing. Imaging studies such as PET-CT may be used in certain lymphoma cases to assess disease spread.
Q: How long does blood cancer treatment last?
Treatment duration depends on the specific subtype and stage of disease. Some therapies last several months, while maintenance treatment or follow-up monitoring may continue for years.
Q: What are the side effects of blood cancer treatment?
Side effects vary based on the treatment used but may include fatigue, lowered immunity, nausea, hair thinning, or temporary changes in blood counts. These effects are closely monitored and managed through supportive care.
Q: Is blood cancer hereditary?
Most blood cancers are not directly inherited. However, certain genetic predispositions may increase risk, and genetic counselling may be recommended in selected cases.
Q: Can blood cancer return after treatment?
Relapse can occur in some cases, which is why structured follow-up and surveillance testing are essential. Advances in targeted therapy, transplantation, and CAR-T cell therapy provide additional options if relapse occurs.
Q: What is the survival rate of blood cancer?
Survival rates vary widely depending on the type of blood cancer, stage at diagnosis, molecular profile, and response to treatment. Many blood cancers today have significantly improved outcomes with modern therapy.
Q: What is the best treatment for blood cancer?
There is no single “best” treatment. The most appropriate therapy depends on the specific subtype, genetic findings, and overall health of the patient. Treatment may include chemotherapy, targeted therapy, immunotherapy, stem cell transplantation, or CAR-T cell therapy.
Q: Is chemotherapy necessary for blood cancer?
Chemotherapy remains an important component of treatment for many blood cancers. However, in some cases, targeted therapy or immunotherapy may be used alone or in combination.
Q: What is a bone marrow transplant?
A bone marrow transplant, also known as stem cell transplantation, involves replacing diseased bone marrow with healthy stem cells to restore normal blood cell production. It may be autologous (using the patient’s own cells) or allogeneic (using donor cells).
Q: Is blood cancer more dangerous in children or adults?
Risk and outcomes depend on the specific type of blood cancer rather than age alone. Some childhood leukaemias respond very well to treatment, while certain adult forms may behave differently. Specialised paediatric and adult haemato-oncology care is essential for optimal outcomes.
Q: Where can I get blood cancer treatment near me in Delhi?
Blood cancer treatment should be delivered at a specialised haemato-oncology centre with access to advanced diagnostics, stem cell transplantation, and cellular therapies. In Delhi, RGCIRC (Rajiv Gandhi Cancer Institute & Research Centre) provides comprehensive blood cancer care within a dedicated transplant and haemato-oncology programme.
Myeloma/ Multiple Myeloma
Myeloma or Multiple Myeloma are same things and is a cancer arising from plasma cells. Plasma cells too are very important component of body’s immune system and reside in bone marrow. Myeloma can cause widespread damage in body including bone weakness or fractures, kidney dysfunction, infections and anemia. Diagnosis of Myeloma depends upon bone marrow tests or a biopsy from affected tissue apart from several blood tests. Treatment of Myeloma consists of chemotherapy or certain targeted immunotherapies and Autologous bone marrow/ hematopoietic stem cell transplantation. With appropriate therapy, a significant number of patients can achieve good disease control and lead a near normal life.
